Veronica Sanchez Bulis - Nov 10, 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: VP, Corporate Controller
Signature: /s/ Mark Meltz, Attorney-in-Fact
Stock symbol: LYEL
Transactions as of: Nov 10, 2025
Transactions value $: -$3,848
Form type: 4
Date filed: 11/12/2025, 08:34 PM
Previous filing: Nov 10, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Bulis Veronica Sanchez	VP, Corporate Controller	C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SUITE 101, SOUTH SAN FRANCISCO	/s/ Mark Meltz, Attorney-in-Fact	2025-11-12	0002095702

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LYEL	Common Stock	Sale	-$3.85K	-239	-2.53%	$16.10	9.21K	Nov 10, 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
F2	The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $16.08 to $16.11 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.